Cargando…
Preclinical and clinical developments for combination treatment of influenza
Antiviral drugs are an important measure of control for influenza in the population, particularly for those that are severely ill or hospitalised. The neuraminidase inhibitor (NAI) class of drugs, including oseltamivir, have been the standard of care (SOC) for severe influenza illness for many years...
Autores principales: | Koszalka, Paulina, Subbarao, Kanta, Baz, Mariana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098076/ https://www.ncbi.nlm.nih.gov/pubmed/35551301 http://dx.doi.org/10.1371/journal.ppat.1010481 |
Ejemplares similares
-
Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model
por: Koszalka, Paulina, et al.
Publicado: (2022) -
Nonreplicating Influenza A Virus Vaccines Confer Broad Protection against Lethal Challenge
por: Baz, Mariana, et al.
Publicado: (2015) -
Influenza antivirals currently in late‐phase clinical trial
por: Koszalka, Paulina, et al.
Publicado: (2017) -
Scientific barriers to developing vaccines against avian influenza viruses
por: Subbarao, Kanta, et al.
Publicado: (2007) -
Advances in Influenza Virus Research: A Personal Perspective
por: Subbarao, Kanta
Publicado: (2018)